0001558370-17-000104.txt : 20170112 0001558370-17-000104.hdr.sgml : 20170112 20170112095455 ACCESSION NUMBER: 0001558370-17-000104 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170111 ITEM INFORMATION: Results of Operations and Financial Condition FILED AS OF DATE: 20170112 DATE AS OF CHANGE: 20170112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNOGEN INC CENTRAL INDEX KEY: 0000855654 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042726691 STATE OF INCORPORATION: MA FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-17999 FILM NUMBER: 17524100 BUSINESS ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781)895-0600 MAIL ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 8-K 1 imgn_currentfolio8k-a.htm 8-K imgn_Current folio_8K-A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington,  D.C. 20549 

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): January 11, 2017

 

ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

Massachusetts

0-17999

04-2726691

(State or other jurisdiction
of incorporation)

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

830 Winter Street, Waltham,  MA 02451

(Address of principal executive offices)   (Zip Code)

 

Registrant's telephone number, including area code: (781) 895-0600

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

ITEM 2.02 – RESULTS OF OPERATION AND FINANCIAL CONDITION

 

On January 11, 2017, ImmunoGen, Inc. (Nasdaq: IMGN)  announced at the 35th Annual JP Morgan Healthcare conference that its cash balance at December 31, 2016 (unaudited) was approximately $160 million.  ImmunoGen expects to announce its financial results for the six-month transition period ended December 31, 2016 on February 3, 2017.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

ImmunoGen, Inc.

 

(Registrant)

 

 

Date: January 12, 2017

/s/ David B. Johnston

 

 

 

David B. Johnston

 

Executive Vice President and Chief Financial Officer